Tumor-released microvesicles as vehicles of immunosuppression - PubMed (original) (raw)
Review
Tumor-released microvesicles as vehicles of immunosuppression
Roberta Valenti et al. Cancer Res. 2007.
Abstract
Tumor-released microvesicles, or exosomes, which are abundant in the body fluids of patients with cancer, are likely to be involved in tumor progression. We recently showed that microvesicles released by human melanoma and colorectal carcinoma cells can promote the differentiation of monocytes to myeloid-derived suppressor cells which support tumoral growth and immune escape. These findings underscore an important role for these extracellular organelles in remodeling tumor-stromal interactions to promote malignancy.
Similar articles
- Tumour-released exosomes and their implications in cancer immunity.
Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Iero M, et al. Cell Death Differ. 2008 Jan;15(1):80-8. doi: 10.1038/sj.cdd.4402237. Epub 2007 Oct 12. Cell Death Differ. 2008. PMID: 17932500 Review. - Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Marigo I, et al. Immunol Rev. 2008 Apr;222:162-79. doi: 10.1111/j.1600-065X.2008.00602.x. Immunol Rev. 2008. PMID: 18364001 Review. - Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Dolcetti L, et al. Cancer Lett. 2008 Aug 28;267(2):216-25. doi: 10.1016/j.canlet.2008.03.012. Epub 2008 Apr 22. Cancer Lett. 2008. PMID: 18433992 Review. - Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers.
Roberson CD, Atay S, Gercel-Taylor C, Taylor DD. Roberson CD, et al. Cancer Biomark. 2010-2011;8(4-5):281-91. doi: 10.3233/CBM-2011-0211. Cancer Biomark. 2010. PMID: 22045359 - Recent advances on the role of tumor exosomes in immunosuppression and disease progression.
Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Filipazzi P, et al. Semin Cancer Biol. 2012 Aug;22(4):342-9. doi: 10.1016/j.semcancer.2012.02.005. Epub 2012 Feb 19. Semin Cancer Biol. 2012. PMID: 22369922 Review.
Cited by
- The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.
Gardani CFF, Diz FM, Dondé LB, Rockenbach L, Laufer S, Morrone FB. Gardani CFF, et al. Front Immunol. 2024 Sep 17;15:1455469. doi: 10.3389/fimmu.2024.1455469. eCollection 2024. Front Immunol. 2024. PMID: 39355246 Free PMC article. Review. - MAP kinase kinase 1 (MEK1) within extracellular vesicles inhibits tumour growth by promoting anti-tumour immunity.
Searles SC, Chen WS, Yee JD, Lee P, Lee CK, Caron C, Neto F, Matei I, Lyden D, Bui JD. Searles SC, et al. J Extracell Vesicles. 2024 Oct;13(10):e12515. doi: 10.1002/jev2.12515. J Extracell Vesicles. 2024. PMID: 39330930 Free PMC article. - IRF5 suppresses metastasis through the regulation of tumor-derived extracellular vesicles and pre-metastatic niche formation.
Roberts BK, Li DI, Somerville C, Matta B, Jha V, Steinke A, Brune Z, Blanc L, Soffer SZ, Barnes BJ. Roberts BK, et al. Sci Rep. 2024 Jul 5;14(1):15557. doi: 10.1038/s41598-024-66168-w. Sci Rep. 2024. PMID: 38969706 Free PMC article. - Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises.
Bandini S, Ulivi P, Rossi T. Bandini S, et al. Cells. 2024 Feb 13;13(4):337. doi: 10.3390/cells13040337. Cells. 2024. PMID: 38391950 Free PMC article. Review. - Myeloid-derived suppressor cells in cancer and cancer therapy.
Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Lasser SA, et al. Nat Rev Clin Oncol. 2024 Feb;21(2):147-164. doi: 10.1038/s41571-023-00846-y. Epub 2024 Jan 8. Nat Rev Clin Oncol. 2024. PMID: 38191922 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources